United States Últimas notícias

Amazon.com (NASDAQ:AMZN) is looking to raise at least $25 billion through a U.S. dollar bond sale, according to Bloomberg News, as the company continues funding AI infrastructure investments.

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 data for TTI-109, a phosphate prodrug of STAT3 inhibitor TTI-101, including up to 60% reductions in STAT3-driven Th17, Tfh, and B cell populations.

Walmart (NASDAQ:WMT) announced extensive price rollbacks on seasonal food items, including ground beef, sodas, and fresh produce to help consumers combat persistent grocery inflation pressures.

Julian Emanuel, Evercore ISI chief equity and quantitative strategist, doesn't believe the Federal Reserve will move on interest rates this year. Emanuel is maintaining his S&P 500 year-end price target of 7,750 even though stocks have become more volatile. He speaks on "Bloomberg Surveillance."

Lumen Technologies (NYSE:LUMN) completed its $475 million acquisition of Alkira, an on-demand networking platform that helps enterprises connect clouds, sites, partners, and AI workloads.

Samsung Electronics fell 6.92% in South Korea after forecasting a 19-fold jump in second-quarter operating profit to ₩89.4 trillion, pressuring chip stocks across global markets.

Kailera Therapeutics (NASDAQ:KLRA) reported topline data from two Jiangsu Hengrui Pharmaceuticals Phase 3 trials of oral GLP-1 agonist HRS-7535/KAI-7535 in China, including mean weight loss of up to 11.1%.

Arthur J Gallagher (NYSE:AJG) announced it has acquired retail insurance broker Wilson M Beck Insurance Services to expand its commercial service footprint across Western Canada.

Klarna (NYSE:KLAR) announced a long-term commercial partnership with Southwest Airlines (NYSE:LUV) to bring flexible, transparent digital payment choices to domestic travelers.

Garmin (NYSE:GRMN) introduced its LiveScope 2 Series, a next-generation live-scanning sonar system designed for anglers with updated transducer technology and improved imaging performance.

Clearmind (NASDAQ:CMND) reported successful formulation-feasibility results for intranasal delivery of MEAI, its lead candidate initially aimed at treating alcohol use disorder.

Vivani Medical (NASDAQ:VANI) signed a new agreement with Novo Nordisk (NYSE:NVO) for a non-exclusive internal evaluation of NPM-139, its semaglutide implant for chronic weight management.